


UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USPTO.GOV

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/922,584	08/03/2001	Kensuke Kuida	VPI/00-115 CIP

CONFIRMATION NO. 9797

FORMALITIES LETTER



OC000000007263647

Andrea L. C. Robidoux
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242

Date Mailed: 01/03/2002

NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

Filing Date Granted

The U.S. Patent and Trademark Office has received your reply on 12/03/2001 to the Notice to File Missing Parts (Notice) mailed 10/03/2001 and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

The required items noted below SHOULD be filed along with any items required above. The filing date of this nonprovisional application will be the date of receipt of the items required above.

- Total additional claim fee(s) for this application is $36.
 - **$36** for **13** total claims over 20.
- The oath or declaration is missing.
 A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- Late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of $130 was not received.
- **The balance due by applicant is $ 166.**

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

MAR 28 2002

VPI00-115 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Not Yet Known

Group Art Unit: Not Yet Known

Applicants: Kuida et al.,

Serial No.: 09/922,584

Filing Date: August 3, 2001

For: ERK-5 DEFICIENT ANIMALS AND METHODS OF INHIBITING ANGIOGENESIS THROUGH THE INHIBITION OF ERK-5

Cambridge, Massachusetts
March 28, 2002

Honorable Commissioner
For Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 C.F.R. §1.821(f)

Sir:

I declare that the information recorded in computer readable form attached hereto is identical to the written sequence listing in the application filed August 3, 2001.

Respectfully submitted,

Andrea L.C. Robidoux
(Reg. No. 47,902)
Agent for Applicants
Vertex Pharmaceuticals Inc.,
130 Waverly Street
Cambridge, MA 02193-4242
(617) 444-6731
(617) 444-6438 (fax)

VPI00-115 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kuida et al.,

Serial No.: 09/922,584

Filing Date: August 3, 2001

For: ERK-5 DEFICIENT ANIMALS AND METHODS OF INHIBITING ANGIOGENESIS THROUGH THE INHIBITION OF ERK-5

Cambridge, Massachusetts
March 28, 2002

Honorable Commissioner
For Patents
Washington, D.C. 20231

Attention: Application Processing Division,
Special Processing and Correspondence
Branch

TRANSMITTAL LETTER FOR EXECUTED DECLARATION AND SEQUENCE LISTING AND DISKETTE

Sir:

Transmitted herewith in response to the Notice Of Incomplete Nonprovisional Application - Filing Date Granted, mailed January 3, 2002, are the following materials relating to the above-identified application:

1. Statement under 37 C.F.R. 1.82.1
Certification of Sequence Listing

2. Diskette containing Sequence Listing and paper copy of sequence list
3. Executed Declaration and Power of Attorney
4. Copy of Notice Of Incomplete Nonprovisional Application - Filing Date Granted
5. Petition for Extension of Time (2 Months)

Applicants hereby authorize the Commissioner to charge Deposit Account No. 50-0725 in the amount of $166.00 Rule 37 C.F.R. 1.26(a)($130.00 late filing of Oath and Declaration and $36.00 for 13 additional claims over 20).

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Andrea L.C. Robidoux (Reg. No. 47,902)
Agent for Applicants
Vertex Pharmaceuticals Inc.
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-6731
Fax.: (617) 444-6483